CP-751,871 single-dose pharmacokinetics and QT interval prolongation evaluated in healthy subjects

Advanced non-hematologic malignancies often present significant treatment challenges, with existing therapies having limited efficacy and considerable side effects. Novel agents are continuously sought to improve outcomes. CP-751,871 (figitumumab) was developed as a potential therapeutic, likely targeting a pathway involved in cancer growth, as evidenced by its use in combination with docetaxel in subsequent trials. Before advancing such compounds to broader clinical use, understanding their pharmacokinetics (PK) and cardiac safety, particularly the effect on the QT interval, is critical in healthy individuals to establish a safe initial dosing profile.